Meca Lallana, J. E., Ayuso, T., Martínez Yélamos, S., Duran, C., Contreras Martín, Y., Herrera Navarro, N., . . . Ricart, J. (2020). Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
Citação norma ChicagoMeca Lallana, José E., et al. Effectiveness of Fingolimod Versus Natalizumab As Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study. 2020.
Citação norma MLAMeca Lallana, José E., et al. Effectiveness of Fingolimod Versus Natalizumab As Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study. 2020.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.